menu
    • menu

    Company profile for Iterion Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Iterion Therapeutics is a clinical-stage biotechnology company developing Tegavivint, a first-in-class novel targeted cancer therapeutic. Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/-catenin signaling pathway, which is implicated in cell proliferation, ...
    Iterion Therapeutics is a clinical-stage biotechnology company developing Tegavivint, a first-in-class novel targeted cancer therapeutic. Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/-catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML) etc.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Iterion TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2450 West Holcombe Boulevard, Houston, Texas 77021
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iteriontherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/iterion-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
    Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint

    20 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share
    Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint
    Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint

    16 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html

    PR NEWSWIRE
    16 May 2023
    Share Share
    Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint
    Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR
    Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR

    08 Apr 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html

    PRNEWSWIRE
    08 Apr 2022
    Share Share
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers

    10 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/

    CLINICALTRIALSARENA
    10 Nov 2021
    Share Share
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
    Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers

    09 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/iterion-phase-i-ii-trial-tegavivint-paediatric-cancers/

    CLINICALTRIALSARENA
    09 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search